Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Recurrence 1Neoplasms 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Cell- and Tissue-Based Therapy × Clear all
NCT06096038 2026-02-20

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
33 enrolled
Head & Neck

Head and Neck Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡